Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder
NCT00073762
Last updated date
ABOUT THIS STUDY
Primary Objective: To compare the antidepressant efficacy and safety of subjects receiving
DVS-233 SR versus subjects receiving placebo.
Secondary Objective: To assess the response of subjects receiving DVS-233 SR for the clinical
global evaluation, functionality, general wellbeing, pain, and absence of symptoms (Hamilton
Psychiatric Rating Scale for Depression, 17-item [HAM-D17] less than or equal to 7) versus
those subjects receiving placebo.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Major Depressive Disorder
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
18-75 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- Outpatients
- Sexually active women participating in the study must use a medically acceptable form of contraception
- Subjects must have a primary diagnosis of major depressive disorder of 4 on Clinical Global Impressions-Severity scale (CGI-S)
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- Treatment with DVS-233 SR at any time in the past
- Treatment with venlafaxine (immediate release [IR] or extended release [ER]) within 90
days of study day 1
- Known hypersensitivity to venlafaxine (IR or ER)
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Major Depressive DisorderA Comparison of Sertraline Versus Venlafaxine XR in the Treatment of Major Depression
NCT00644982
- Cairns, Queensland
- Everton Park, Queensland
- North Cairns, Queensland
- Box Hill, Victoria
- Heidelberg, Victoria
- West Heidelberg, Victoria
- West Perth, Western Australia
- Adana,
- Ankara,
- Diyarbakir,
- Istanbul,
- Izmir,
- Izmit,
- Malatya,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Major Depressive DisorderStudy Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder
NCT00384033
- Beverly Hills, California
- Burbank, California
- Encino, California
- Los Alamitos, California
- Newport Beach, California
- Northridge, California
- Orange, California
- Pasadena, California
- Upland, California
- South Miami, Florida
- St. Petersburg, Florida
- Edwardsville, Illinois
- Farmington Hills, Michigan
- Flint, Michigan
- Okemos, Michigan
- Clementon, New Jersey
- Dayton, Ohio
- Portland, Oregon
- Philadelphia, Pennsylvania
- Salt Lake City, Utah
- Seattle, Washington
- Brown Deer, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Major Depressive DisorderRelapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
NCT00887224
- Beverly Hills, California
- Encino, California
- Los Alamitos, California
- Orange, California
- Upland, California
- Aurora, Colorado
- Jacksonville, Florida
- South Miami, Florida
- St. Petersburg, Florida
- St. Petersburg, Florida
- Atlanta, Georgia
- Smyrna, Georgia
- Hoffman Estates, Illinois
- Rockville, Maryland
- New York, New York
- New York, New York
- Rochester, New York
- Dayton, Ohio
- Portland, Oregon
- San Antonio, Texas
- Seattle, Washington
- Edmonton, Alberta
- Medicine Hat, Alberta
- Kelowna, British Columbia
- Vancouver, British Columbia
- Bathurst, New Brunswick
- Burlington, Ontario
- Ottawa, Ontario
- Toronto, Ontario
- Gatineau, Quebec
- Pointe-Claire, Quebec
- Sherbrooke, Quebec
- Santiago,
- Santiago,
- Santiago,
- Medellin, Antioquia
- Barranquilla, Atlantico
- Bogota, Cundinamarca
- Bucamaranga, Santander
- Rijeka,
- Zagreb,
- Tallinn,
- Tallinn,
- Tartu,
- Voru,
- Vöru,
- Espoo,
- Helsinki,
- Joensuu,
- Kuopio,
- Seinajoki,
- Tampere,
- Turku,
- Caen,
- Dole,
- Douai,
- Orvault,
- Rennes,
- Liepaja,
- Sigulda,
- Sigulda,
- Strenci,
- Kaunas,
- Kaunas,
- Vilius,
- Vilnius,
- Vilnius,
- Vilnius,
- Skorzewo, Poznan
- Szczecin,
- Torun,
- Tuszyn,
- Wroclaw,
- Zuromin,
- Craiova, Dolj
- Brasov,
- Bucharest,
- Bucuresti,
- Bucuresti,
- Cluj Napoca,
- Bojnice,
- Bratislava,
- Liptovsky Mikulas,
- Michalovce,
- Rimavska Sobota,
- Trencin,
- Cape Town, Western Cape
- Durban,
- Paarl,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Major Depressive DisorderStudy Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD)
NCT01056289
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title ICMJE | Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder | |||
| Official Title ICMJE | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Two Fixed Doses (200 Mg, Or 400 Mg) Of DVS-233 SR In Adult Outpatients With Major Depressive Disorder | |||
| Brief Summary | Primary Objective: To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo. Secondary Objective: To assess the response of subjects receiving DVS-233 SR for the clinical global evaluation, functionality, general wellbeing, pain, and absence of symptoms (Hamilton Psychiatric Rating Scale for Depression, 17-item [HAM-D17] less than or equal to 7) versus those subjects receiving placebo. | |||
| Detailed Description | Not Provided | |||
| Study Type ICMJE | Interventional | |||
| Study Phase ICMJE | Phase 3 | |||
| Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Primary Purpose: Treatment | |||
| Condition ICMJE | Major Depressive Disorder | |||
| Intervention ICMJE | Drug: DVS-233 SR | |||
| Study Arms ICMJE | Not Provided | |||
| Publications * | Thase ME, Fayyad R, Cheng RF, Guico-Pabia CJ, Sporn J, Boucher M, Tourian KA. Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis. Curr Med Res Opin. 2015 Apr;31(4):809-20. doi: 10.1185/03007995.2015.1020365. Epub 2015 Mar 26. | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status ICMJE | Completed | |||
| Actual Enrollment ICMJE | 375 | |||
| Original Enrollment ICMJE | Not Provided | |||
| Actual Study Completion Date ICMJE | September 2004 | |||
| Actual Primary Completion Date | September 2004 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender ICMJE |
| |||
| Ages ICMJE | 18 Years to 75 Years (Adult, Older Adult) | |||
| Accepts Healthy Volunteers ICMJE | No | |||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries ICMJE | Not Provided | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number ICMJE | NCT00073762 | |||
| Other Study ID Numbers ICMJE | 3151A1-308? | |||
| Has Data Monitoring Committee | Not Provided | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement ICMJE | Not Provided | |||
| Responsible Party | Not Provided | |||
| Study Sponsor ICMJE | Wyeth is now a wholly owned subsidiary of Pfizer | |||
| Collaborators ICMJE | Not Provided | |||
| Investigators ICMJE |
| |||
| PRS Account | Wyeth is now a wholly owned subsidiary of Pfizer | |||
| Verification Date | August 2009 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | ||||